Skip to content

    Astrazeneca Phar

    ASTRAZENGood
    Healthcare·8 Aug 2022
    Management Summary

    AstraZeneca India's FY22 performance was characterized by a transition phase where legacy blockbusters faced intense generic pressure, offset by robust growth in new-age Oncology and Respiratory therapies. While total revenue dipped slightly by 2%, the company successfully defended market leadership in brands like Brilinta despite 30+ generic competitors. Management is pivoting towards a 'beyond-the-pill' digital strategy and preparing for a foray into Rare Diseases following the global Alexion acquisition.

    Highlights

    8

    • Revenue from sales stood at ₹761.4 crores, a slight decline of 2% YoY due to generic competition in key brands.

    • Total Comprehensive Income for the year was reported at ₹59.9 crores.

    • Oncology portfolio emerged as a major growth engine, with Tagrisso contributing 22% of total sales (₹167.5 crores).

    • Respiratory business grew by an unprecedented 82% YoY, driven by Symbicort and the launch of Fasenra.

    • The company declared a total dividend of ₹10 per share (₹2 interim + ₹8 final) for FY22, representing a ~40% payout ratio.

    • Management confirmed a significant price reduction of 48% for Dapagliflozin (Forxiga) to counter generic entry.

    • Maintained a strong liquidity position with a cash balance of ₹448.4 crores and remains debt-free.

    • Inventory holding improved to 67 days compared to 75 days in the previous year.

    Concerns

    1

    • Generic Erosion of Key Brands

    What Changed1

    vs Q4 FY23

    Risks discussed4 → 3 (-1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹761.4 Cr-2%YoY
    2. 02Total Comprehensive Income₹59.9 Cr
    3. 03Dividend Per Share₹10
    4. 04Cash Balance₹448.4 Cr
    5. 05Employee Cost % of Sales30.2%

    Segment breakdown

    Healthcare
    ₹761.4 Cr Revenue₹167.5 Cr Tagrisso Sales₹112.7 Cr Brilinta Sales₹84.4 Cr Lynparza Sales
    List

    Guidance & targets

    3
    CategoryTargetPriority
    Revenue
    Total Sales Target
    $1 billion
    		Low
    Margin
    Respiratory Portfolio Contribution
    15-20%
    		Medium
    Dividend
    Dividend Payout Ratio
    50%
    		Medium

    Risks & concerns

    4
    RiskSeverity

    Generic Erosion of Key Brands

    Over 30 generics launched for Ticagrelor (Brilinta) and 100+ for SGLT2i (Forxiga), leading to a 48% price cut. — Both acknowledged

    high

    Rising Employee Costs

    Employee costs as a percentage of sales rose from 28.26% to 30.23% YoY. — Management acknowledged

    medium

    Regulatory and Funding Hurdles for Rare Diseases

    The high cost of rare disease drugs requires a government-supported funding framework to be viable in India. — Management acknowledged

    medium

    Areas of Evasion(1)

    • Specific patent expiry dates for Lynparza, Tagrisso, and Imfinzi were referred to the Company Secretary rather than answered on the call.

    Q&A highlights

    3

    “To quantify our price reduction was 48%. The generics continue to compete and continue to go lower and lower in pricing.”

    Confirms the massive margin pressure on the CVRM portfolio (Dapagliflozin) due to patent expiries.

    asked by Amit Thawani

    2 min read5 chapters

    Detailed Narrative

    01

    Oncology Dominance and Pipeline Acceleration

    Oncology has become the primary growth engine for AstraZeneca India, with Tagrisso leading the lung cancer segment with ₹167.5 crores in sales. The company is now the second fastest-growing MNC in the Indian oncology market, moving up two spots in value rankings since 2020. Management is fast-tracking the pipeline with 14 positive Phase 3 readouts globally, aiming to bring molecules like Enhertu and Lokelma to the Indian market subject to regulatory approvals.

    02

    Generic Headwinds in CVRM Portfolio

    The Cardiovascular, Renal, and Metabolism (CVRM) segment faced severe pricing pressure as Dapagliflozin (Forxiga) saw a 48% price reduction to stay competitive against 100+ generic entrants. Despite this, Brilinta maintained market leadership in the oral anti-platelet category even with 30+ generics in the fray. Management noted that while volumes for Forxiga grew by 4%, the revenue impact of price erosion led to an overall slight decline in net sales for the year.

    03

    Respiratory Segment as the Next Growth Frontier

    The Respiratory business delivered an 82% growth surge, which management attributes to a 'remarkable comeback' by Symbicort and the successful launch of the biologic Fasenra. Currently, respiratory accounts for only ~2% of sales, but the company aims to scale this to 15-20% in the medium term. To support this, they are establishing 15 'precision clinics' across India to improve the diagnosis and management of severe asthma.

    04

    Capital Allocation and Dividend Strategy

    AstraZeneca remains a debt-free company with a substantial cash reserve of ₹448.4 crores. While shareholders pushed for a 50%+ dividend payout ratio, management defended the current 40% payout (₹10 per share), citing the need for significant reinvestment to reach their long-term $1 billion sales target. They emphasized that dividends are on an 'increasing trend' but must be balanced against the high cost of launching innovative therapies.

    05

    Digital Transformation and 'Beyond the Pill' Initiatives

    The company is aggressively adopting an Omni-channel approach to connect with Healthcare Professionals (HCPs), reporting a 65% increase in email open rates. Digital initiatives like 'Project Heartbeat' and 'Take Care of Me' are moving the business model from selling products to providing holistic 'systems of care.' Over 1,000 HCPs have already adopted their virtual clinic platform, treating over 1.3 million diabetes patients.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.